Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)

Bagirath Gangadharan, PhD, Birgit Reipert, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karin Fijn van Draat, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, Margaret V. Ragni, MD MPH, Hassan M. Yaish, MD, Amy D. Shapiro, MD, Donald L Yee, MD, Vlad Calin Radulescu, MD, Elena Santagostino, Deborah Brown, MD

Blood (2017) 130 (Supplement 1): 88.

https://doi.org/10.1182/blood.V130.Suppl_1.88.88

Published: 2017

Journal Articles

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Birgit M Reipert, PhD, Bagirath Gangadharan, PhD, Christoph J Hofbauer, PhD, Fritz Scheiflinger, PhD, Joel Bowen, Elizabeth Donnachie, PhD, Karen Fijvandraat, MD, Ralph A. Gruppo, MD, Jenny Klintman, MD PhD, Christoph Male, MD, Catherine E. McGuinn, MD, Shannon L. Meeks, MD, Michael Recht, MD PhD, M V Ragni, MD, Hassan M Yaish, Elena Santagostino, MD PhD, Deborah L Brown, MD

Blood (2016) 128 (22): 328.

https://doi.org/10.1182/blood.V128.22.328.328

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede, Christoph J. Hofbauer, Sonja Werwitzke, Paul Knöbl, Saskia Gottstein, Rüdiger E. Scharf, Jürgen Heinz, Jürgen Groß, Katharina Holstein, Christiane Dobbelstein, Fritz Scheiflinger, Armin Koch, Birgit M. Reipert

Blood (2016) 127 (19): 2289–2297.

https://doi.org/10.1182/blood-2015-09-672774

Published: 2016

Includes: Supplemental data

Journal Articles

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke

Michelle A. H. Sonneveld, Moniek P. M. de Maat, Marileen L. P. Portegies, Maryam Kavousi, Albert Hofman, Peter L. Turecek, Hanspeter Rottensteiner, Fritz Scheiflinger, Peter J. Koudstaal, M. Arfan Ikram, Frank W. G. Leebeek

Blood (2015) 126 (25): 2739–2746.

https://doi.org/10.1182/blood-2015-05-643338

Published: 2015

Includes: Supplemental data

Journal Articles

Quantification of ADAMTS-13 Activity and Antigen from the Same Sample by a Newly Developed Combi-Actibind Assay (TECHNOZYM® ADAMTS-13).

Sabine Geiter, MS, Sebastién Colle, Ms, Paul A. Kyrle, MD, Fritz Scheiflinger, PhD, Bernd R. Binder, MD, Helga Vetr, PhD

Blood (2006) 108 (11): 1065.

https://doi.org/10.1182/blood.V108.11.1065.1065

Published: 2006

Journal Articles

Anti-Factor IX Antibodies Displaying FVIIIa-Like Activity.

Randolf J. Kerschbaumer, Michael Dockal, Rosing Jan, Fritz Scheiflinger

Blood (2006) 108 (11): 1713.

https://doi.org/10.1182/blood.V108.11.1713.1713

Published: 2006

Journal Articles

Technozym ® ADAMTS-13 ANTIGEN ELISA - A New Assay for Specific Quantification of the vWF Cleaving Protease ADAMTS-13.

Helga Vetr, PhD, Sabine Geiter, Fritz Scheiflinger, PhD, Michael Dockal, PhD, Bernd R. Binder, PhD

Blood (2005) 106 (11): 4098.

https://doi.org/10.1182/blood.V106.11.4098.4098

Published: 2005

Journal Articles

ADAMTS13 autoantibody detection by quantitative immunoblotting

Katalin Váradi, Jutta Schreiner, Barbara Plaimauer, Manfred Rieger, Fritz Scheiflinger, Paul Knöbl, Peter L. Turecek, Hans P. Schwarz

Blood (2003) 102 (5): 1932–1933.

https://doi.org/10.1182/blood-2003-05-1688

Published: 2003

NARROW

Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)

Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke

Quantification of ADAMTS-13 Activity and Antigen from the Same Sample by a Newly Developed Combi-Actibind Assay (TECHNOZYM® ADAMTS-13).

Anti-Factor IX Antibodies Displaying FVIIIa-Like Activity.

Technozym ® ADAMTS-13 ANTIGEN ELISA - A New Assay for Specific Quantification of the vWF Cleaving Protease ADAMTS-13.

ADAMTS13 autoantibody detection by quantitative immunoblotting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only